Nurix Therapeutics (NRIX) Stock Overview
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NRIX Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nurix Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.81 |
| 52 Week High | US$28.23 |
| 52 Week Low | US$8.20 |
| Beta | 1.8 |
| 1 Month Change | -0.58% |
| 3 Month Change | 52.27% |
| 1 Year Change | 180.54% |
| 3 Year Change | 190.65% |
| 5 Year Change | -27.84% |
| Change since IPO | 35.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRIX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.9% | -4.4% | -0.2% |
| 1Y | 180.5% | 39.9% | 14.8% |
Return vs Industry: NRIX exceeded the US Biotechs industry which returned 39.9% over the past year.
Return vs Market: NRIX exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| NRIX volatility | |
|---|---|
| NRIX Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NRIX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NRIX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 317 | Arthur Sands | www.nurixtx.com |
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
Nurix Therapeutics, Inc. Fundamentals Summary
| NRIX fundamental statistics | |
|---|---|
| Market cap | US$2.73b |
| Earnings (TTM) | -US$341.35m |
| Revenue (TTM) | US$36.77m |
Is NRIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRIX income statement (TTM) | |
|---|---|
| Revenue | US$36.77m |
| Cost of Revenue | US$340.93m |
| Gross Profit | -US$304.17m |
| Other Expenses | US$37.18m |
| Earnings | -US$341.35m |
Last Reported Earnings
May 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.29 |
| Gross Margin | -827.31% |
| Net Profit Margin | -928.44% |
| Debt/Equity Ratio | 0% |
How did NRIX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 23:44 |
| End of Day Share Price | 2026/09/10 00:00 |
| Earnings | 2026/05/31 |
| Annual Earnings | 2025/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nurix Therapeutics, Inc. is covered by 26 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| Zhiqiang Shu | Berenberg |